OctoPlus announces agreement with a US biotechnology company on its controlled release technology
OctoPlus N.V. announced that it has signed an agreement with a US biotechnology company relating to the use of OctoPlus' controlled release technology.
Under the contract, OctoPlus will develop a controlled release version of a product currently in clinical development using its proprietary drug delivery technology PolyActive®. The client will reimburse OctoPlus for its activities under the agreement. Further financial terms of the agreement are not disclosed.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.